AstraZeneca, Merck's Lynparza picks up new NICE recommendation

AstraZeneca and Merck's Lynparza has received a positive recommendation from England's National Institute for Health and Care Excellence for the treatment of BRCA-mutated, relapsed, platinum-sensitive high-grade ovarian, fallopian tube or peritoneal cancer.